Hepatitis B vaccination:
safety issues

Viral Hepatitis Prevention Board meeting

Guido François
Executive VHPB Secretariat

February 2003

Executive VHPB Secretariat, Department of Epidemiology and Social Medicine, University of Antwerpen, Universiteitsplein 1, BE-2610 Antwerpen, Belgium.
E-mail: guido.francois@ua.ac.be; Tel. +32 (0)3 820 25 23; Fax +32 (0)3 820 26 40.
Hepatitis B vaccination: safety issues

This document is meant as a short introduction to the literature concerning potential adverse events following hepatitis B vaccination and their impact, the subject of the Viral Hepatitis Prevention Board (VHPB) meeting in Geneva, March 13-14, 2003.

The objectives of the meeting include:
1. To review potential adverse events following hepatitis B vaccination.
2. To update the points of view regarding safety issues and describe new developments.
3. To describe the impact of safety issues in an international perspective.
4. To discuss communication strategies to counter vaccination 'scare'.

The following subjects will be treated and discussed in separate sessions:
- Adverse events following hepatitis B vaccination: multiple sclerosis; effects of thiomersal; effects of aluminium; leukaemia; and autoimmune diseases.
- Impact of safety issues and points of view from France, Germany, Scotland, Israel, and UNICEF, combined with considerations on the global impact and litigation issues.
- Communication: the Global Advisory Committee on Vaccine Safety (GACVS) and its communication strategy; the role of the industry; considerations on The Brighton Collaboration; countering the anti-vaccination movement and vaccination 'scare'; and working with the media.
- Conclusions and recommendations.

The conclusions resulting from the meeting will include amendments on points of view, guidelines, and existing recommendations issued by international organisations and institutes. In accordance with the VHPB tradition, the obtained information and points of view will be compiled and will appear in one of the next issues of Viral Hepatitis. A concise scientific report will be published in a peer-reviewed journal.

Relevant background information, suggestions for further reading, and additional sources of information are included in the reference list below.
Literature


Aston R. Scares, scams and sickness: countering the anti-vaccination lobby. Vaccines: Children & Practice 2002; 5:30-34.


Centers for Disease Control and Prevention. Overview of vaccine safety


Duclos P. How to improve communication on vaccine safety at international level? Vaccine 2001; 20(Suppl 1):S96-S97

Duclos P. Safety of immunization and adverse events following vaccination against hepatitis B. EASL International Consensus Conference on Hepatitis B, Session 2: Epidemiology and Prevention, 2002, 12 p


Institute of Medicine. Immunization safety review: Hepatitis B vaccine and demyelinating neurologic disorders, 2002, 106 p

Institute of Medicine. Immunization safety review: Multiple immunizations and immune dysfunction, 2002, 138 p

Institute of Medicine. Immunization safety review: Thimerosal-containing vaccines and neurodevelopmental disorders, 2001, 122 p


Offit PA. Vaccines and autism. Immunization Action Coalition, Item #P2065 (9/02)


Sullivan LW. Maintaining the public's trust in immunization. EPI Newsl 1998; 20:5

U.S. Food and Drug Administration. Thimerosal in vaccines


Wolfe RM, Sharp LK. Anti-vaccinationists past and present. BMJ 2002; 325:430-432

World Health Organization. Supplementary information on vaccine safety. Part 2: Background rates of adverse events following immunization. WHO/V&B/00.36

World Health Organization. Vaccines, Immunization and Biologicals. Immunization safety: a priority